Clinical Observation Of Quyu Yangxin Prescription On Stable Angina Pectoris Of Coronary Heart Disease(Phlegm And Blood Atasis) And Its Influence On Lp-PLA2 And NO Levels

Objective:In this study,by observing the effect of Quyu Yangxin Prescription on angina pectoris symptom score,TCM syndrome score,quality of life score,electrocardiogram,blood lipid,serum NO and Lp-PLA2 in patients with stable angina pectoris(phlegm and blood stasis)of coronary heart disease,the clinical efficacy of Quyu Yangxin Prescription in the treatment of stable angina pectoris was evaluated and its possible mechanism was discussed.Methods:A total of 60 patients with stable angina pectoris of coronary heart disease with phlegm and blood stasis were included in this study and randomly divided into control group and experimental group with 30 pa tients each.The control group was treated with conventional Western m edicine,and the experimental group was treated with Quyu Yangxin Pre scription on the basis of the control group for 4 weeks.The symptoms of angina pectoris,TCM syndromes,quality of life,electrocardiogram,blood lipids,serum NO and Lp-PLA2 levels and safety indicators were observed before and after treatment.Results:1.Angina symptom score and efficacy: After treatment,the score of angina symptoms in both groups was lower than that before treatment(P <0.05),and the symptoms of angina were improved.The total effective rate was 66.7% in the control group and 89.7% in the experimental group.The experiment group was superior to the control group(P <0.05).2.TCM syndrome score and efficacy: After treatment,the TCM syndrome score of both groups was lower than that before treatment(P <0.05)of patients decreased compared to before treatment(P <0.05),and the TCM syndrome was reduced.The total effective rate was 63.3% in the control group and 93.1% in the experimental group.The experimental group was superior to the control group(P<0.05).3.Quality of life score: After treatment,the SF-8 score of patients in both groups was higher than that before treatment(P <0.05),and the quality of life was improved.The experimental group was better than the control group(P <0.05).4.Electrocardiogram efficacy: The efficacy of electrocardiogram was50.0% in the control group and 60.1% in the experimental group,and there was no significant difference between the efficacy of the experimental group and the control group(P >0.05).5.Blood lipid level: After treatment,TC,TG,and LDL-C in both groups decreased compared to before treatment(P <0.05),and the levels in the experimental group were lower than those in the control group(P <0.05).After treatment,HDL-C increased compared to before treatment(P <0.05),and there was no significant difference between the efficacy of the experimental group and the control group(P >0.05).6.Endothelial function factor level: After treatment,the NO level of patients in both groups increased compared to before treatment(P <0.05),while the experimental group was higher than the control group(P <0.05).7.Inflammatory factor level: After treatment,the level of Lp-PLA2 in the two groups decreased compared to that before treatment(P <0.05),while the level of Lp-PLA2 in the experimental group was lower than that in the control group(P <0.05).Conclusion:1.Quyu Yangxin Prescription can improve the symptoms of angina,TCM syndromes and quality of life in patients with stable angina pectoris of coronary heart disease(phlegm and blood stasis).2.The mechanism of Quyu Yangxin Prescription in the treatment of patients with stable angina pectoris of coronary heart disease(phlegm and blood stasis)may be related to reducing blood lipid levels,increasing blood NO levels,and reducing blood Lp-PLA2 levels.